Mylan’s stock tumbled Tuesday to its lowest point since 2012 after the generic drug giant reported a loss for the first quarter and lower-than-expected revenue because of weaker sales in the U.S. and Europe.

Shares gave up $6.73, or 24 percent, to close at $21.53. It was the biggest one-day drop since June 2000.

The stock was trading in the low $70s in 2015 when Mylan rejected a buyout offer at $82 a share from rival Teva Pharmaceutical Industries in Israel.

Revenue was $2.5 billion for the quarter, down 7 percent from $2.7 billion in the first quarter last year.

Advertise with us

The company cited pricing pressure and remediation work at its flagship plant in Morgantown, W.Va., where it is working to fix manufacturing deficiencies outlined in a November warning letter from the Food and Drug Administration involving cross-contamination of drug ingredients and other issues.

Mylan posted a first-quarter loss of $25 million, or 5 cents per share, down from profits of $87 million, or 17 cents, a year earlier.

On an adjusted basis, the company earned 82 cents per share, down 15 percent from a year ago, but better than analysts’ consensus estimate of 80 cents.

In a conference call with analysts, CEO Heather Bresch had no news to report from a strategic review the board has been conducting since August.

“A tremendous amount of work is being done,” she said, adding that she believed results would be reported “in the near term.”

Advertise with us

Ms. Bresch had indicated in February that the review, which is aimed at “unlocking the true value” of the company, was nearing completion. Possible moves could include a sale or merger, spinning off one or more businesses, or taking the company private.

Cowen analyst Ken Cacciatore said Mylan’s business was eroding.

“This will likely end badly,” he wrote in a note to clients after Tuesday’s earnings release.

“Like all generic franchises, there are only so many undifferentiated acquisitions that can be made to cover the constant downward deterioration in the base businesses. At a certain point, the new product cycle needs to materialize. But even in this case with quality launches [of new products], it is still not enough,” he said. “We would avoid.”

Mylan, which is incorporated in the Netherlands, is run from executive offices in Cecil.

Advertise with us

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.

This story was updated at 5 p.m., May 7, 2019.